CAS: 1347304-18-0; (E)-N-Methyl-2-((3-(2-(Pyridin-2-yl)Vinyl)-1H-Indazol-6-yl)Sulfinyl)Benzamide
- 英文名称(E)-N-Methyl-2-((3-(2-(Pyridin-2-yl)Vinyl)-1H-Indazol-6-yl)Sulfinyl)Benzamide
- 中文名称N-甲基-2-[[3-[(1E)-2-(2-吡啶基)乙烯基]-1H-吲唑-6-基]亚磺酰基]苯甲酰胺
- IUPAC名称(E)-N-methyl-2-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)sulfinyl)benzamide
- 其它别名Axitinib Impurity A; Axitinib Sulfoxide; N-Methyl-2-[[3-[(1E)-2-(2-Pyridinyl)Ethenyl]-1H-Indazol-6-Yl]Sulfinyl]Benzamide; N-Methyl-2-[[3-[(E)-2-Pyridin-2-Ylethenyl]-1H-Indazol-6-Yl]Sulfinyl]Benzamide; Axitinib Impurity 5/axitinib Sulfoxide/n-Methyl-2-[[3-[(1E)-2-(2-Pyridinyl)Ethenyl]-1H-Indazol-6-Yl]Sulfinyl]-Benzamide; Benzamide, N-Methyl-2-[[3-[(1E)-2-(2-Pyridinyl)Ethenyl]-1H-Indazol-6-Yl]Sulfinyl]-; Axitinib C
- CAS编号1347304-18-0
- MFCD编号:MFCD30747237
- EINECS号:886-850-0
- FDA UNII编号:55P8GY3IEK
- 分子式:C22H18N4O2S分子量:402.48
- 产品CID: 530954
物理性质
MSDS等安全信息
欧盟法规
C&L通报上下游产品
axitinib合成工艺路线路线简述
海关参考信息
- 2901210000-乙烯
2912110000-甲醛
2912210000-苯甲醛
2933310010-吡啶 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T; KEYNOTE-426 Investigators. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16. 380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.
3: Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R, Nosov D, Pouliot F, Melichar B, Vynnychenko I, Azevedo SJ, Borchiellini D, McDermott RS, Bedke J, Tamada S, Yin L, Chen M, Molife LR, Atkins MB, Rini BI. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open- label, phase 3 trial. Lancet Oncol. 2020 Dec;21(12):1563-1573. doi: 10.1016/S1470-2045(20)30436-8. Epub 2020 Oct 23. Erratum in: Lancet Oncol. 2020 Dec;21(12):e553. 26(11):1733-1741. doi: 10.1038/s41591-020-1044-8. Epub 2020 Sep 7.
5: Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B, Kollmannsberger C, Gravis-Mescam G, Uemura M, Lee JL, Grimm MO, Gurney H, Schmidinger M, Larkin J, Atkins MB, Pal SK, Wang J, Mariani M, Krishnaswami S, Cislo P, Chudnovsky A, Fowst C, Huang B, di Pietro A, Albiges L. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020 Aug;31(8):1030-1039. doi: 10.1016/j.annonc.2020.04.010. Epub 2020 Apr 25.
合成参考文献
合成方法参考DOI号:10.1124/dmd.113.056531
📝 需求与反馈
尽可能描述清楚需求与问题信息
